Exelixis (NASDAQ:EXEL) will be issuing its quarterly earnings data after the market closes on Monday, February 26th. Analysts expect the company to announce earnings of $0.12 per share for the quarter.
Shares of Exelixis (EXEL) opened at $29.51 on Friday. The company has a market capitalization of $8,730.00, a PE ratio of 60.22, a price-to-earnings-growth ratio of 0.82 and a beta of 1.84. Exelixis has a twelve month low of $18.03 and a twelve month high of $32.50.
EXEL has been the topic of a number of recent analyst reports. Zacks Investment Research raised Exelixis from a “hold” rating to a “strong-buy” rating and set a $35.00 price target on the stock in a report on Tuesday, January 2nd. William Blair reissued an “outperform” rating on shares of Exelixis in a report on Monday, February 12th. BidaskClub raised Exelixis from a “hold” rating to a “buy” rating in a report on Thursday, January 25th. Oppenheimer reissued a “hold” rating on shares of Exelixis in a report on Tuesday, December 19th. Finally, Cann reissued a “hold” rating on shares of Exelixis in a report on Thursday, January 4th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $32.13.
In other news, Director Alan M. Garber sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $30.30, for a total transaction of $454,500.00. Following the completion of the transaction, the director now owns 64,829 shares in the company, valued at $1,964,318.70. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 5.10% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.